This resource was selected by SMI Adviser content partners and approved by the SMI Adviser clinical expert team for inclusion in the knowledge base.
This comprehensive meta-analysis of cohort studies, reflecting clinical practice more than RCTs, found clozapine to be associated with better effectiveness outcomes than [other second-generation antipsychotics], despite more severely ill patients being treated with clozapine, but with significantly greater risk of cardiometabolic adverse outcomes, both of which require consideration when making treatment choices,” the authors concluded.